Sanofi
SNY
$59.15
$1.452.51%
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | 11.26B | 11.57B | 5.72B | 13.02B | |
| Total Other Revenue | 912.47M | 683.47M | 1.27B | 798.90M | |
| Total Revenue | 12.17B | 12.25B | 6.99B | 13.82B | |
| Cost of Revenue | 3.81B | 3.65B | 2.50B | 4.18B | |
| Gross Profit | 8.36B | 8.60B | 4.49B | 9.64B | |
| SG&A Expenses | 2.82B | 2.90B | 1.25B | 2.81B | |
| Depreciation & Amortization | 479.69M | 537.09M | 319.13M | 611.69M | |
| Other Operating Expenses | 949.78M | 1.57B | 1.59B | 626.93M | |
| Total Operating Expenses | 10.47B | 10.50B | 7.37B | 10.04B | |
| Operating Income | 1.70B | 1.75B | -385.70M | 3.78B | |
| Income Before Tax | 1.14B | 1.52B | -1.35B | 3.38B | |
| Income Tax Expenses | 202.53M | 321.82M | -312.45M | 612.78M | |
| Earnings from Continuing Operations | 938.05M | 1.20B | -1.04B | 2.76B | |
| Earnings from Discontinued Operations | -197.20M | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -12.79M | -4.31M | 3.69M | -14.15M | |
| Net Income | 728.06M | 1.20B | -668.03M | 2.75B | |
| EBIT | 1.70B | 1.75B | -385.70M | 3.78B | |
| EBITDA | 2.59B | 2.70B | 327.05M | 4.61B | |
| EPS Basic | 0.58 | 0.96 | -0.54 | 2.19 | |
| Normalized Basic EPS | 0.78 | 0.80 | -- | -- | |
| EPS Diluted | 0.58 | 0.95 | -0.54 | 2.19 | |
| Normalized Diluted EPS | 0.78 | 0.79 | -- | -- | |
| Average Basic Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | |
| Average Diluted Shares Outstanding | 1.25B | 1.26B | 1.26B | 1.25B | |
| Dividend Per Share | 4.18 | -- | 4.05 | -- | |
| Payout Ratio | -- | -- | 82.48% | -- | |
